Fig. 5From: Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitroEffects of LS on the expression levels of inflammatory mediators and the expression of the key proteins related to the NF-κB/MAPK signaling pathway in SARS-CoV-2-infected mice. A The mRNA expression of the IFN-α, IFN-γ, MCP-1 and IP-10 in the lung of the infected mice were detected by RT-qPCR analysis at the fifth d.p.i.; B The expression of the key proteins related to the NF-κB/MAPK signaling pathway was examined by western blotting; C The expression of phosphorylation of nuclear translocation of NF-κB p65 was determined by immunohistochemistry at the fifth d.p.i. Scale bar = 400 µm. a mock infected mice treated with PBS (normal control, NC); b SARS-CoV-2-infected mice treated with PBS (viral control, Virus); c SARS-CoV-2-infected mice treated with remdesivir; d–f SARS-CoV-2-infected mice treated with LS (160, 80 and 40 mg/kg). *P < 0.05; **P < 0.01; ***P < 0.001, compared with viral controlBack to article page